BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Dalton Pharma Services Announces a Successful Health Canada Audit


11/30/2011 12:07:48 PM

Toronto, Ontario (PRWEB) November 30, 2011 -- Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced the company has received ‘Compliant’ rating from Health Canada following the completion of the regulatory agency’s Good Manufacturing Practices inspection of the facility. The license allows Dalton Pharma Services to continue manufacturing, testing, packaging and distributing sterile drug products including powders for injection. The company is licensed for the commercial manufacture, testing and distribution of solid oral dosage forms. The license ensures that Dalton can continue manufacturing, testing and shipping commercial products for existing clients in Canada and the EU and to attract and fulfill commercial pharmaceutical manufacturing relationships.

"The confirmation of Dalton’s GMP compliance in the current climate of increased regulatory vigilance is a testament to our Quality group’s adherence to the high standards of current GMP’s" said Peter Pekos, President and CEO. “Dalton is celebrating 25 years in business supplying innovative solutions to the pharmaceutical industry and we are thrilled to be able to play a part in our clients’ success in developing the medicines of the future. Dalton’s clients can start with Dalton Pharma Services in clinical trial manufacturing and stay with Dalton through commercial manufacturing,” he continued.

Ildiko Riss, Director of Quality stated “In view of news reports of recent serious quality issues in the contract manufacturing industry noted by regulators we consider the success of the audit as a re-affirmation of Dalton’s commitment to continuous improvement of our quality systems. We would also like to extend our thanks to our clients for their audits of Dalton throughout the years. Dalton has benefited tremendously from these audits and we are grateful for the auditors from around the world who have provided invaluable feedback to our team strengthening our company’s compliance.”

Accelerating drug development and manufacturing of novel medicines continues to be a strategic priority of the pharma industry. Dalton’s provision of integrated services by combining commercial manufacture of sterile, solid dose pharmaceuticals and API in one location provides its clients a distinct competitive advantage in bringing their products to the market.

About Dalton:

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and aseptic filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts aseptic fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton’s analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients. Further information can be found at http://www.dalton.com.

Contact:

Peter Pekos

President & CEO

Dalton Pharma Services Inc.

349 Wildcat Road

Toronto, Ontario

Tel: 416-661-2102


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->